number of participants with diabetes by trial cholesterol treatment trialists' (ctt)...
DESCRIPTION
Proportional effects on cause-specific mortality per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25TRANSCRIPT
![Page 1: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/1.jpg)
Number of participants with diabetes by trial
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 2: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/2.jpg)
Baseline characteristics of participants presenting with or without diabetes
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 3: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/3.jpg)
Proportional effects on cause-specific mortality per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 4: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/4.jpg)
Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 5: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/5.jpg)
Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol in participants
with and without diabetes by history of vascular disease
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 6: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/6.jpg)
Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol by baseline prognostic factors in participants with diabetes
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 7: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/7.jpg)
Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol by baseline lipid profi le in participants with diabetes
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25
![Page 8: Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet…](https://reader035.vdocuments.net/reader035/viewer/2022070616/5a4d1c137f8b9ab0599f7fc9/html5/thumbnails/8.jpg)
Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol, by year, in participants with and without diabetes
Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25